Aldosterone antagonists vs placebo or usual care
Cardiovascular and cerebrovascular morbidity · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
- Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes onlyRR 0.38 [0.18, 0.76]3 studies · 328 participantsModerate